Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating whether certain host factors, including the variety and makeup of intestinal microbiota and genetic markers, are linked to a higher chance of recurrence of Clostridioides difficile infection CDI. The study aims to create a predictive tool that uses epidemiological, clinical, genetic, and microbiologic data to identify patients at greater risk of CDI coming back, within an optimized CDI management setting. This is a multicenter, prospective observational study involving adults diagnosed with CDI according to IDSA criteria. Participants will be part of a stewardship program designed to improve CDI management and enable early detection of CDI recurrence. Blood samples will be collected for genetic testing, and stool samples will be analyzed to study the intestinal microbiome. The study will monitor patients diagnosed with CDI over time without introducing experimental treatments. Throughout the study, researchers will assess the occurrence of CDI recurrence within the first 8 weeks after therapy ends and reinfection between 8 and 24 weeks post-therapy. They will also track hospital readmissions due to CDI during the 24 weeks following treatment completion. Data will be analyzed to identify predictors of recurrence, and the predictive tools accuracy will be evaluated. Participants may expect periodic monitoring as part of the study lasting until December 2029.
Actively Recruiting
Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.